Emerging Cellular Therapies for Pancreatic Regeneration in Type 1 Diabetes Mellitus: Biological Foundations, Experimental Models, and Clinical Perspectives
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Type 1 diabetes mellitus is a chronic autoimmune disease characterized by the selective destruction of pancreatic beta cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin therapy. Although advances in insulin delivery and glucose monitoring have improved glycemic control, these approaches do not address the underlying autoimmune pathology or restore endogenous insulin production. Growing evidence indicates that pancreatic damage in type 1 diabetes mellitus arises from a complex interaction between autoreactive immune cells, pro-inflammatory cytokine networks, and intrinsic beta-cell stress responses, while the endocrine pancreas retains a limited but clinically relevant regenerative capacity. This biological context has driven increasing interest in cellular therapies aimed at pancreatic regeneration. Recent advances in stem cell biology have enabled the generation of insulin-producing cells from embryonic stem cells, induced pluripotent stem cells, and adult progenitor populations, offering scalable alternatives to donor islet transplantation. In parallel, cellular reprogramming and transdifferentiation strategies, including alpha-to-beta cell conversion and epigenetic modulation, have demonstrated the ability to restore insulin secretion in experimental models. These approaches are supported by sophisticated in vitro systems, such as pancreatic organoids and three-dimensional culture platforms, as well as diverse animal models that enable functional, metabolic, and immunological evaluation of regenerative therapies. Despite encouraging preclinical results and early-phase clinical trial data showing safety and preliminary efficacy, major challenges remain. Recurrent autoimmunity, graft survival, tumorigenicity risk, and the need for immunosuppression continue to limit long-term success. Emerging immune protection strategies, including hypoimmune cell engineering, encapsulation technologies, and immune tolerance induction, represent critical avenues for improving durability and safety.
Fields of Study & Subjects
Pancreatic function and diabetes
Diabetes and associated disorders
Tissue Engineering and Regenerative Medicine
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 March 2026
- Language
- EN